Table 1 Clinicopathological characteristics of PCa patients

Age

 Median (IQR)

65 (59.5–70.0)

 Range (Min, Max)

52–78

  < 65

22 (48.9%)

  ≥ 65

23 (51.1%)

Total PSA (t-PSA)

(ng/ml)

Median (IQR)

15.28

(8.61–38.30)

Range (Min, Max)

1.05–92.21

 < 4 ng/ml

4 (8.9%)

 4–10 ng/ml

12 (26.7%)

 10–20 ng/ml

12 (26.7%)

 > 20 ng/ml

17 (37.8%)

Gleason Score (GS)

 < 7

15 (33.3%)

 = 7

15 (33.3%)

 > 7

15 (33.3%)

Clinical T-stage

 T2a

6 (13.3%)

 T2b

12 (26.7%)

 T2c

15 (33.3%)

 T3a or T3b

12 (26.7%)

Lymph node metastasis

 N0

30 (66.7%)

 N1

15 (33.3%)

Distant metastasis

 M0 or Mx

41 (91.1%)

 M1

4 (8.9%)

TNM stage

 I-II

25 (55.6%)

 III-IV

20 (44.4%)

Log0.5 MMAB expression

 Median (IQR)

13.823837

(13.254977–14.245784)

 Range (Min, Max)

11.968522–15.233100

Log0.5 IGFBP3 expression

 Median (IQR)

12.619003

(11.692416–13.321569)

 Range (Min, Max)

10.851545–14.289084

Log0.5 HNRNPA2B1 expression

 Median (IQR)

11.927719

(11.106794–12.651593)

 Range (Min, Max)

10.123230–13.496253